But we’re going to try to keep things in very much in sync between the various types of patients, whether you’re insured, uninsured, commercial, Medicare. So that kind of is a little bit of more flavor around it rather than a real specific number that I’m giving you, but expect all those components, especially you’ll see in this first kind of 12-month period.
Tina Ventura: Thanks, Jon. Lisa, it looks like we have time for one more question, please.
Operator: Our next question is coming from Andrea Tan of Goldman Sachs.
Andrea Tan: Maybe one question here on the prescriptions that have come through. Just wondering if you’re able to speak about the dynamics that you’re seeing to date. Is that generally one prescription per specialist or maybe multiple prescriptions per specialists?
Bill Sibold: Thanks, Andrea. It varies, right? I mean everyone starts with one, so to speak, or actually someone started with more than that. But one of the things we expect to see is in this top 6,000 or this target 6,000 is it’s going to go beyond one and they’re going to go pretty deep actually because we know they have the patience and we know that there’s a lot of favorable belief about Rezdiffra. So over time, we’re going to see, again, this notion of breadth and depth, and it’s going to be concentrated in that top 6,000. So still pretty early. I mean, look, again, with just what we found is that the physicians until drugs available weren’t giving a lot of thought to how they’re going to process all their patients, right?
Now the drug is available, they’re making it part of their pathway in their practice, and that takes a little bit of time to think how they’re going to do it. But we’re really encouraged. Patients are being prescribed, patients are getting on drug. So we’re kind of fulfilling our promise. We’re trying to change lives here. and it’s really exciting. And maybe I’ll just end on that and say this is a really great and exciting opportunity. As you heard me, Sam more excited about the opportunity now than I was 6 months ago or 3 months ago. And it’s just — I can’t tell you how much fun it is to be out there with a product that’s so meaningful in a disease that has had absolutely nothing. And we get to set the bar for all others that come. There’s — it’s rare that you get an opportunity to be the first one to establish how do you engage with companies.
What’s the expectation you set for patient services and everything along the way, we have that opportunity as the leader. And our intent is to go out there, and we are leading like leaders. First launch, but we have a really experienced team. We know what we’re doing. We have the resource, we have the product, the opportunity is there. It just takes time to get it right, build the foundation as we wire the system and we’ll put ourselves in a great position to win and be the leader in this space.
Tina Ventura: Thanks, Andrea, and thanks, Lisa, and thank you all for your time and interest today. This concludes our call. A replay of the webcast will be available on our website in approximately 2 hours. So thank you so much for joining us.
Operator: Ladies and gentlemen, thank you for your participation in today’s conference. You may now all disconnect. Have a wonderful day.
